<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029323</url>
  </required_header>
  <id_info>
    <org_study_id>22062020</org_study_id>
    <nct_id>NCT05029323</nct_id>
  </id_info>
  <brief_title>Validation of a Novel Simplified Head up Tilt Test (HUTT) Protocol Versus the Conventional Protocol</brief_title>
  <official_title>Validation of a Novel Simplified Head up Tilt Test (HUTT) Protocol Versus the Conventional Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the positivity rate associated with a novel simplified&#xD;
      Tilt-Table (TT) test protocol versus the conventional TT protocol&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with unexplained syncope at initial evaluation with indication to perform a Head&#xD;
      up tilt test (HUTT) will be randomized to &quot;conventional&quot; HUTT protocol or &quot;fast&quot; HUTT&#xD;
      protocol characterized by a stabilization phase of 5 min in the supine position; a passive&#xD;
      phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after&#xD;
      300 micrograms NTG sublingual spray. The novel simplified &quot;fast&quot; HUTT protocol has been&#xD;
      designed to provide non inferior positivity rates as compared with the conventional protocol&#xD;
      in the selected population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">January 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HUTT positivity rate during passive phase</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The study endpoint is the number of patients who experienced syncope during the passive phase of HUTT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HUTT positivity rate during active phase</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The study endpoint is the number of patients who experienced syncope during the active phase of HUTT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The type of HUTT-induced syncope during passive phase</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The secondary study endpoint is the number of patients with cardioinhibitory HUTT-syncope during the passive phase of HUTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type of HUTT-induced syncope during active phase</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The secondary study endpoint is the number of patients with cardioinhibitory HUTT-syncope during the active phase of HUTT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Syncope</condition>
  <condition>Syncope;Heat Induced</condition>
  <arm_group>
    <arm_group_label>Conventional HUTT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to &quot;conventional&quot; HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fast HUTT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to &quot;fast&quot; HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fast HUTT</intervention_name>
    <description>Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.</description>
    <arm_group_label>Fast HUTT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Conventional HUTT</intervention_name>
    <description>Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.</description>
    <arm_group_label>Conventional HUTT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with unexplained syncope at initial evaluation and indication to perform&#xD;
             HUTT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  PM/ICD device recipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Russo, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincenzo Russo, MD PhD</last_name>
    <phone>+390817062355</phone>
    <email>vincenzo.russo@unicampania.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Campania &quot;Luigi Vanvitelli&quot;</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Russo</last_name>
      <email>vincenzo.russo@unicampania.it</email>
    </contact>
    <contact_backup>
      <last_name>Vincenzo Russo</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Vincenzo Russo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

